|
Gene: SEC14L4 |
Gene summary for SEC14L4 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SEC14L4 | Gene ID | 284904 |
Gene name | SEC14 like lipid binding 4 | |
Gene Alias | TAP3 | |
Cytomap | 22q12.2 | |
Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | B2RMR2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
284904 | SEC14L4 | HCC1_Meng | Human | Liver | HCC | 3.04e-09 | -7.57e-02 | 0.0246 |
284904 | SEC14L4 | HCC1 | Human | Liver | HCC | 2.05e-06 | 8.26e-01 | 0.5336 |
284904 | SEC14L4 | HCC2 | Human | Liver | HCC | 3.31e-19 | 3.44e+00 | 0.5341 |
284904 | SEC14L4 | HCC5 | Human | Liver | HCC | 7.13e-18 | 1.60e+00 | 0.4932 |
284904 | SEC14L4 | Pt13.a | Human | Liver | HCC | 9.68e-04 | -1.01e-01 | 0.021 |
284904 | SEC14L4 | S028 | Human | Liver | HCC | 1.31e-03 | 1.77e-01 | 0.2503 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | |
Skin | AK | |
Skin | SCCIS | |
Skin | cSCC | |
Thyroid | HT |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SEC14L4 | SNV | Missense_Mutation | rs780473734 | c.170G>A | p.Arg57Gln | p.R57Q | Q9UDX3 | protein_coding | deleterious(0.02) | probably_damaging(0.945) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
SEC14L4 | SNV | Missense_Mutation | c.571N>C | p.Val191Leu | p.V191L | Q9UDX3 | protein_coding | tolerated(0.2) | benign(0.062) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD | |
SEC14L4 | SNV | Missense_Mutation | novel | c.824N>T | p.Arg275Met | p.R275M | Q9UDX3 | protein_coding | tolerated(0.07) | benign(0.019) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SEC14L4 | SNV | Missense_Mutation | novel | c.77N>C | p.Leu26Pro | p.L26P | Q9UDX3 | protein_coding | deleterious(0.02) | possibly_damaging(0.808) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SEC14L4 | SNV | Missense_Mutation | c.860G>A | p.Gly287Asp | p.G287D | Q9UDX3 | protein_coding | deleterious(0.03) | benign(0.114) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
SEC14L4 | SNV | Missense_Mutation | c.986N>T | p.Ser329Ile | p.S329I | Q9UDX3 | protein_coding | deleterious(0.01) | benign(0.062) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
SEC14L4 | SNV | Missense_Mutation | rs368386943 | c.1022N>A | p.Arg341His | p.R341H | Q9UDX3 | protein_coding | tolerated(0.09) | benign(0.188) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD |
SEC14L4 | SNV | Missense_Mutation | rs564814217 | c.1096N>A | p.Asp366Asn | p.D366N | Q9UDX3 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SEC14L4 | SNV | Missense_Mutation | c.859G>T | p.Gly287Cys | p.G287C | Q9UDX3 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-A5-A0GA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | PD | |
SEC14L4 | SNV | Missense_Mutation | rs774887890 | c.856N>T | p.Arg286Cys | p.R286C | Q9UDX3 | protein_coding | deleterious(0.05) | probably_damaging(0.948) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |